The Phase 1 trial is a multi-arm dose escalation study evaluating TSC-100, TSC-101, or HCT alone in patients with AML, ALL or MDS undergoing haploidentical allogeneic HCT with reduced intensity conditioning.

Source: https://forextv.com/top-news/tscan-therapeutics-presents-initial-phase-1-clinical-results-on-tsc-100-and-tsc-101-at-the-65th-american-society-of-hematology-annual-meeting-and-exposition/

We have also licensed treosulfan, part of a preparative regimen for allogeneic hematopoietic stem cell transplantation to be used in combination with fludarabine, for commercialization in the United States and Canada.

Source: https://www.marketscreener.com/quote/stock/MEDEXUS-PHARMACEUTICALS-I-49601873/news/Medexus-Expects-Record-Revenue-for-Fiscal-Q3-2023-and-Provides-Business-Update-42719657/?utm_medium=RSS&utm_content=20230112